Baseline Study

Last updated

Project Baseline is a broad effort to map human health led by Verily Life Sciences (formerly Google Life Sciences), Alphabet, Inc.'s health sciences division, and was announced in the Wall Street Journal on July 24, 2014. [1] It begins with the ProjectBaseline Study, which will collect phenotypic health data from approximately 10,000 participants over the course of at least four years. The project employs experts from widely varying fields including science, medicine, user experience and design, engineering and patient advocacy. [1] The project is not the first one to aim to collect data on many individuals for medical purposes, but it aims to collect a much larger amount of data covering a broader array of topics than its predecessors. [1] De-identified Project Baseline study data will be available to qualified researchers for exploratory analysis in the future. Qualified external researchers may apply through applications reviewed by the Proposal Review and Publications Committee and Scientific Executive Committee. [2]

Contents

Purpose

The Project Baseline study is the first initiative of Project Baseline, a broader effort designed to develop a well-defined reference, or "baseline," of good health as well as a rich data platform that may be used to better understand the transition from health to disease and identify additional risk factors for disease. [2] The study will collect comprehensive health information both within and outside the four walls of a clinic. Within the clinic, a broad group of participants - including those who are exceptionally healthy, at-risk of disease, and with overt disease - will be providing deep data on a diverse set of measurements with repeat sampling over the course of four years. [3] To bridge these encounters, Verily has developed tools such as the investigational Study Watch to allow participants to provide insights throughout their everyday lives. [4]

That means the Project Baseline study dataset will include clinical, molecular, imaging, self-reported, behavioral, environmental, sensor and other health-related measurements. To organize this information, Verily is developing infrastructure that can process multi-dimensional health data - much of which have never been combined for an individual. [3]

The project also hopes to enable doctors to predict the onset of diseases such as cancer and heart disease far earlier than is currently possible. Organizers hope this will move medicine toward an era centered on prevention rather than treatment. [5] In addition, the study aims to identify biomarkers that make certain people more or less susceptible to various diseases. [1]

Methodology

The project began in the summer of 2014, when Google began recruiting volunteers to collect bodily fluids such as urine, blood, saliva and tears for a pilot study. The public facing launch was in April 2017, and since then participants have begun enrolling. [6] Sites include Duke University School of Medicine and Stanford Medicine, [1] whose institutional review boards will also monitor the study and make sure the data from it is not misused, according to Verily. Verily also stated that all the data in the study would be anonymized before researchers would have access to it. [7]

Ethical concerns

Specialist online reporting service STAT News reported in 2016 that the contract for testing of the 200 patients for the study's pilot phase had been awarded without competitive bidding to the California Health & Longevity Institute, a luxury health clinic largely owned by Verily Executive Chairman and Founder Andrew Conrad that offers medical and cosmetic para-medical services and alternative medicine in a spa-like setting. [8] The report said that Conrad had stated that the clinic had the advantage of having all the testing equipment needed for the study in one location, but neither he nor officials from the clinic would disclose what relevant experience the clinic had in conducting the complex research required for the project. [8] Conrad further stated that the contract had been vetted by Google X's compliance and ethics officers when Verily was still part of that division, and a spokesperson stated that Conrad had recused himself from the decision-making project, but a former Verily employee claimed that Google X's vetting of the deal was perfunctory. [8]

In April 2017, a Verily spokeswoman confirmed that Andy Conrad had divested from the California Health & Longevity Institute. [9]

See also

Related Research Articles

<span class="mw-page-title-main">Veterinarian</span> Health professional who treats non-human animals

A veterinarian (vet) is a medical professional who practices veterinary medicine. They manage a wide range of health conditions and injuries in non-human animals. Along with this, veterinarians also play a role in animal reproduction, health management, conservation, husbandry and breeding and preventive medicine like nutrition, vaccination and parasitic control as well as biosecurity and zoonotic disease surveillance and prevention.

<span class="mw-page-title-main">Clinical trial</span> Phase of clinical research in medicine

Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial—their approval does not mean the therapy is 'safe' or effective, only that the trial may be conducted.

<span class="mw-page-title-main">Health informatics</span> Computational approaches to health care

Health informatics is the study and implementation of computer structures and algorithms to improve communication, understanding, and management of medical information. It can be viewed as a branch of engineering and applied science.

<span class="mw-page-title-main">Women's Health Initiative</span> Long-term U.S. health study

The Women's Health Initiative (WHI) was a series of clinical studies initiated by the U.S. National Institutes of Health (NIH) in 1991, to address major health issues causing morbidity and mortality in postmenopausal women. It consisted of three clinical trials (CT) and an observational study (OS). In particular, randomized controlled trials were designed and funded that addressed cardiovascular disease, cancer, and osteoporosis.

<span class="mw-page-title-main">UK Biobank</span> Long-term biobank study of 500,000 people

UK Biobank is a large long-term biobank study in the United Kingdom (UK) which is investigating the respective contributions of genetic predisposition and environmental exposure to the development of disease. It began in 2006. UK Biobank has been cited as an important resource for cancer research.

<span class="mw-page-title-main">Drug development</span> Process of bringing a new pharmaceutical drug to the market

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug. The entire process—from concept through preclinical testing in the laboratory to clinical trial development, including Phase I–III trials—to approved vaccine or drug typically takes more than a decade.

Google Health encompasses the health and wellbeing initiatives of Google, including Fitbit and a range of other features and integrations. Google Health started in 2008 as an attempt to create a repository of personal health information in order to connect doctors, hospitals and pharmacies directly. The Google Health project was discontinued in 2012, but the Google Health portfolio re-established in 2018 before being redescribed in 2022 as an "effort" rather than a distinct division.

<span class="mw-page-title-main">Sanford Burnham Prebys Medical Discovery Institute</span> Non-profit medical research institute

Sanford Burnham Prebys is a 501(c)(3) non-profit medical research institute focusing on basic and translational research, with major research programs in cancer, neurodegeneration, diabetes, infectious, inflammatory, and childhood diseases. The institute also specializes in stem cell research and drug discovery technologies.

A glossary of terms used in clinical research.

Generation Scotland is a biobank, a resource of biological samples and information on health and lifestyle from thousands of volunteer donors in Scotland.

<span class="mw-page-title-main">Thomas R. Insel</span> American neuroscientist

Thomas Roland Insel is an American neuroscientist, psychiatrist, entrepreneur, and author who led the National Institute of Mental Health (NIMH) from 2002 until November 2015. Prior to becoming Director of NIMH, he was the founding Director of the Center for Behavioral Neuroscience at Emory University in Atlanta, Georgia. He is best known for research on oxytocin and vasopressin, two peptide hormones implicated in complex social behaviors, such as parental care and attachment. He announced on Sept. 15, 2015, that he was resigning as the director of the NIMH to join the Life Science division of Google X. On May 8, 2017, CNBC reported that he had left Verily Life Sciences. Insel is a Co-founder with Richard Klausner and Paul Dagum of a digital mental health company named "Mindstrong," a Bay-area startup. He has also co-founded Humanest Care, NeuraWell Therapeutics, and MindSite News and is a member of the scientific advisory board for Compass Pathways, a company that is developing the psychedelic drug psilocybin to treat depression and other mental health disorders. His book, Healing: Our Path from Mental Illness to Mental Health was published by Penguin Random House in February, 2022.

<span class="mw-page-title-main">Robert C. Green</span> American geneticist

Robert C. Green is an American medical geneticist, physician, and public health researcher. He directs the Genomes2People Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women's Hospital and the Broad Institute, and is Director of the Preventive Genomics Clinic at Brigham and Women's Hospital. Research led by Green includes clinical and research aspects of genomic and precision medicine, including the development and disclosure of Alzheimer's disease risk estimates and one of the first prospective studies of direct-to-consumer genetic testing services. He has studied the implementation of medical sequencing in healthy adults, newborns, and active duty military personnel. As of 2020, he is leading the first research collaboration to explore return of genomic results and better understand penetrance in a population-based cohort of underrepresented minorities. He has led the Preventive Genomics Clinic at Brigham and Women's Hospital since its creation in 2019.

<span class="mw-page-title-main">Linda P. Fried</span> American epidemiologist

Linda P. Fried is an American geriatrician and epidemiologist, who is also the first female Dean of Columbia University's Mailman School of Public Health. Her research career is focused on frailty, healthy aging, and how society can successfully transition to benefit from an aging population.

<span class="mw-page-title-main">Christopher G. Chute</span> American medical researcher

Christopher G. Chute is a Bloomberg Distinguished Professor at Johns Hopkins University, physician-scientist and biomedical informatician known for biomedical terminologies and health information technology (IT) standards. He chairs the World Health Organization Revision Steering Group for the revision of the International Classification of Diseases (ICD-11).

<span class="mw-page-title-main">Verily</span> Life sciences research organization

Verily Life Sciences LLC, also known as Verily, is Alphabet Inc.'s research organization devoted to the study of life sciences. The organization was formerly a division of Google X, until August 10, 2015, when Sergey Brin announced that the organization would become an independent subsidiary of Alphabet Inc. with restructuring completed on October 2, 2015. On December 7, 2015, Google Life Sciences was renamed Verily.

The All of Us Research Program is a research program created in 2015 during the tenure of Barack Obama with $130 million in funding that aims to make advances in tailoring medical care to the individual. The mission of All of Us is to accelerate health and medical breakthroughs, enabling individualized prevention, treatment and care.

<span class="mw-page-title-main">Andrew Conrad</span> American geneticist (born 1964)

Andrew J. Conrad is an American geneticist who heads Verily, a life sciences division of Alphabet Inc. As its chief executive officer, Conrad has recruited a multidisciplinary team of chemists, doctors, engineers, behavioral scientists and data scientists to research health and disease.

Dynamic consent is an approach to informed consent that enables on-going engagement and communication between individuals and the users and custodians of their data. It is designed to address the many issues that are raised by the use of digital technologies in research and clinical care that enable the wide-scale use, linkage, analysis and integration of diverse datasets and the use of AI and big data analyses. These issues include how to obtain informed consent in a rapidly-changing environment; growing expectations that people should know how their data is being used; increased legal and regulatory requirements for the management of secondary use of data in biobanks and other medical research infrastructure. The approach started to be implemented in 2007 by an Italian group who introduced the ways to have an ongoing process of interaction between researcher and participant where "technology now allows the establishment of dynamic participant–researcher partnerships." The use of digital interfaces in this way was first described as 'Dynamic Consent' in the EnCoRe project. Dynamic Consent therefore describes a personalised, digital interface that enables two-way communication between participants and researchers and is a practical example of how software can be developed to give research participants greater understanding and control over how their data is used. It also enables clinical trial managers, researchers and clinicians to know what type of consent is attached to the use of data they hold and to have an easy way to seek a new consent if the use of the data changes. It is able to support greater accountability and transparency, streamlining consent processes to enable compliance with regulatory requirements.

<span class="mw-page-title-main">21st Century Cures Act</span> Bill enacted by the 114th United States Congress

The 21st Century Cures Act is a United States law enacted by the 114th United States Congress in December 2016 and then signed into law on December 13, 2016. It authorized $6.3 billion in funding, mostly for the National Institutes of Health. The act was supported especially by large pharmaceutical manufacturers and was opposed especially by some consumer organizations.

<span class="mw-page-title-main">Merative</span> U.S. healthcare company

Merative L.P., formerly IBM Watson Health, is an American medical technology company that provides products and services that help clients facilitate medical research, clinical research, real world evidence, and healthcare services, through the use of artificial intelligence, data analytics, cloud computing, and other advanced information technology. Merative is owned by Francisco Partners, an American private equity firm headquartered in San Francisco, California. In 2022, IBM divested and spun-off their Watson Health division into Merative. As of 2023, it remains a standalone company headquartered in Ann Arbor with innovation centers in Hyderabad, Bengaluru, and Chennai.

References

  1. 1 2 3 4 5 Barr, Alistair (24 July 2014). "Google's New Moonshot Project: the Human Body". The Wall Street Journal . Retrieved 26 July 2014.
  2. 1 2 "The Baseline Study". ClinicalTrials.gov . 15 May 2017.
  3. 1 2 Mega, Jessica (19 April 2017). "Why Baseline?". Project Baseline blog . Retrieved 20 June 2017.
  4. He, David (14 April 2017). "Introducing Verily Study Watch". Verily blog . Retrieved 20 June 2017.
  5. Stone, Jeff (25 July 2014). "Baseline Study, New Google 'Moonshot,' Continues Health-First Trend After Google Lenses, Project Loon". International Business Times . Retrieved 26 July 2014.
  6. "Verily Launches Landmark Study with Duke and Stanford as First Initiative of Project Baseline" (PDF). Project Baseline . 19 April 2017. Archived from the original (PDF) on 25 October 2017. Retrieved 20 June 2017.
  7. Alter, Charlotte (28 July 2014). "Google Seeks Human Guinea Pigs for Health Project". Time . Retrieved 2 August 2014.
  8. 1 2 3 Piller, Charles (7 April 2016). "Google's biotech venture hit by ethical concerns over deal with luxury clinic". STAT News. Retrieved 12 June 2016.
  9. Regalado, Antonio (19 April 2017). "Google's Health Study Seeks 10,000 Volunteers to GiveUp Their Medical Secrets". MIT Technology Review . Retrieved 20 June 2017.